The company has a robust global footprint, with significant operations in the US (37% of global revenues, $891 million enterprise), Europe, Japan, Australia, and emerging markets like India, Brazil, Mexico, and South Africa. Its US subsidiary, Lupin Pharmaceuticals Inc., is the 4th largest generic player by prescriptions, leading in 46 of 140 marketed products. Lupin operates 15 state-of-the-art manufacturing facilities across India, the US, Brazil, and Mexico, and invests heavily in R&D, focusing on complex generics, biosimilars, and specialty drugs like inhalation and injectables. Strategic acquisitions, such as Medisol (France, 2023), Medquímica (Brazil, 2015), and Gavis/Novel (US, 2015), have bolstered its global reach and portfolio.
Lupin’s India business, contributing 34% of revenue, outperforms the market with a 3.4% share, driven by chronic therapies. The company emphasizes digital transformation, leveraging AI for innovation, and maintains a strong ESG framework. Despite challenges like regulatory hurdles (e.g., FDA warnings) and pricing pressures, Lupin has achieved double-digit growth, supported by a deep pipeline (154 ANDA filings pending FDA approval) and patient-centric initiatives like NovaShakti and Jeet. However, recent setbacks, such as the Myrbetriq patent litigation loss in 2025, pose risks. Lupin’s focus on innovation, affordability, and strategic expansion positions it for sustained growth in the global pharma landscape.
Latest News on Lupin
Lupin achieves top ESG rating from CDP for its efforts in addressing climate change and water security.
Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin’s position among the world’s most sustainable and transparent companies. The double “A” rating reflects Lupin’s significant progress in mitigating climate risks, reducing carbon emissions, and ensuring responsible water management across its operations.
Compared to its previous ratings, Lupin has made substantial improvements, upgrading from “A-” in 2024 and “B” and “C” in 2023 for climate and water, respectively. This remarkable achievement demonstrates Lupin’s commitment to sustainability and its proactive initiatives to minimize its environmental impact. Ramesh Swaminathan, Executive Director and Global CFO, expressed pride in earning the double “A” rating, attributing it to the company’s innovative approaches, collaborative efforts, and transparent practices.
Lupin’s sustainability endeavors have also been recognized by S&P Global, which awarded the company an ESG score of 91 in 2025. This achievement places Lupin among an elite group of companies worldwide that have surpassed the 90-point threshold, demonstrating its best-in-class sustainability performance. The CDP’s strict framework has played a significant role in shaping and accelerating Lupin’s climate initiatives, driving ongoing progress and commitment to establishing new sustainability standards.
The recognition from CDP and S&P Global underscores Lupin’s dedication to generating lasting value for its communities and the planet. As a global pharma leader, Lupin is committed to reducing its environmental impact through innovation, collaboration, and transparency, setting a high standard for sustainability in the industry. With its exceptional achievements, Lupin continues to demonstrate its position as a responsible and sustainable business leader, driving positive change and promoting a more environmentally conscious future.
Lupin Achieves Prestigious CDP Double ‘A’ Rating for Excellence in Climate Change Mitigation and Water Stewardship
Lupin, a global pharmaceutical company, has achieved a significant milestone in its sustainability journey by earning a double ‘A’ rating from CDP (formerly known as the Carbon Disclosure Project) for its leadership in climate action and water security. This prestigious rating recognizes Lupin’s efforts to reduce its environmental impact and mitigate the risks associated with climate change and water scarcity.
CDP is a non-profit organization that assesses companies’ environmental performance and transparency. The double ‘A’ rating is the highest rating given by CDP, and it indicates that Lupin has demonstrated exceptional leadership and commitment to environmental stewardship. Lupin is one of only a few companies globally to achieve this rating, and it is a testament to the company’s dedication to sustainability.
Lupin’s climate action efforts have focused on reducing greenhouse gas emissions, transitioning to renewable energy sources, and implementing energy-efficient technologies. The company has set ambitious targets to reduce its carbon footprint, including a goal to become carbon neutral by 2050. Lupin has also implemented various initiatives to promote sustainable practices throughout its supply chain, including working with suppliers to reduce their environmental impact.
In addition to its climate action efforts, Lupin has also demonstrated leadership in water security. The company has implemented water conservation measures across its operations, including rainwater harvesting and wastewater treatment. Lupin has also engaged with local communities to promote water conservation and support watershed development projects.
The double ‘A’ rating from CDP is a significant achievement for Lupin, and it reflects the company’s commitment to sustainability and environmental responsibility. Lupin’s leadership in climate action and water security will not only reduce its environmental impact but also contribute to the well-being of local communities and the planet as a whole. The company’s sustainability efforts are aligned with the United Nations’ Sustainable Development Goals (SDGs), and it is working to integrate the SDGs into its business strategy.
Overall, Lupin’s double ‘A’ rating from CDP is a testament to the company’s dedication to sustainability and environmental stewardship. The company’s efforts to reduce its environmental impact and promote sustainable practices will have a positive impact on the environment, local communities, and its business operations. As a responsible corporate citizen, Lupin is committed to continuing its sustainability journey and making a positive difference in the world.
Lupin Earns Top CDP A Rating for Efforts in Combating Climate Change and Conserving Water
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional performance in Climate Change and Water Security. This recognition is a testament to Lupin’s commitment to sustainability and transparency, placing the company among the world’s leading organizations that prioritize environmental stewardship.
Lupin’s double ‘A’ rating in Climate and Water demonstrates its proactive approach to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This achievement represents a significant improvement from the company’s previous ratings, with a substantial enhancement from ‘A-‘ in 2024 and ‘B’ in 2023 for climate, and ‘C’ for water. This progress reflects Lupin’s dedication to continuous improvement and its efforts to establish new sustainability standards.
The company’s Executive Director, Ramesh Swaminathan, attributed this achievement to Lupin’s innovative approaches, collaborative efforts, and transparency. He emphasized that the CDP’s framework has helped shape and accelerate the company’s climate initiatives, driving ongoing progress. Lupin’s commitment to sustainability is also reflected in its S&P Global ESG score of 91 in 2025, which is a best-in-class global achievement. This score positions Lupin among a select group of companies worldwide that have surpassed the 90-point threshold, demonstrating its exceptional performance in environmental, social, and governance (ESG) aspects.
Lupin’s achievement is a significant milestone in the pharmaceutical industry, highlighting the company’s dedication to reducing its environmental impact while generating lasting value for its communities and the planet. By prioritizing sustainability and transparency, Lupin is setting a high standard for the industry and demonstrating its commitment to creating a better future for all stakeholders. Overall, Lupin’s double ‘A’ rating from CDP and its exceptional ESG score are a testament to the company’s leadership in sustainability and its efforts to make a positive impact on the environment.
Lupin Achieves Top ESG Score from CDP for Efforts in Combating Climate Change and Ensuring Water Security – Reported by Chennai Patrika.
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition solidifies Lupin’s position as a global leader in championing sustainability and transparency. The company’s double ‘A’ rating in Climate and Water is a testament to its commitment to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations.
This achievement represents a substantial improvement from Lupin’s previous ratings, with the company moving from ‘A-‘ in 2024 to ‘A’ in 2025, and from ‘B’ in 2023 to ‘A’ in 2025 for climate and water, respectively. This significant year-over-year progress demonstrates Lupin’s dedication to sustainability and its proactive initiatives aimed at reducing its environmental impact.
Ramesh Swaminathan, Executive Director, Global CFO and Head of API Plus SBU at Lupin, expressed pride in the company’s achievement, stating that Lupin has advanced its efforts to reduce environmental impact through innovation, collaboration, and transparency. He also acknowledged the role of CDP’s strict framework in shaping and accelerating the company’s climate initiatives, fostering ongoing progress.
In addition to the CDP rating, Lupin has also achieved an S&P Global ESG score of 91 in 2025, a best-in-class global achievement that positions the company among a distinguished group of companies worldwide that have surpassed the 90-point threshold. This recognition demonstrates Lupin’s commitment to establishing new sustainability standards and generating lasting value for its communities and the planet. Overall, Lupin’s achievements in sustainability and environmental responsibility underscore its position as a responsible and forward-thinking global pharmaceutical leader.
US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue and margin driver for Indian drugmakers such as Dr Reddy’s Laboratories, Cipla, Zydus Lifesciences, and Sun Pharma. However, with the patent expiry in January 2026, these companies will have to offload their remaining quotas, leading to a decline in sales.
Analysts expect a sector-wide decline in earnings before interest, taxes, depreciation, and amortization (Ebitda) margins by 150 basis points year-on-year, with companies such as Dr Reddy’s, Cipla, and Zydus Lifesciences likely to be affected. The decline in Revlimid sales will be a significant contributor to this margin pressure, with prices expected to erode sharply as players look to offload remaining quotas. Additionally, other factors such as increased generic price competition in the US market, higher research and development (R&D) expenses, and rising selling, general, and administrative (SG&A) costs will also weigh on margins.
Despite these challenges, analysts remain optimistic about the sector’s overall revenue growth, with expectations of 8-11% growth driven by steady domestic growth and traction in other markets. Domestic sales are projected to outpace the broader Indian pharmaceutical market’s 10.1% growth, with the chronic segment showing particular strength. Companies such as Lupin, Sun Pharma, and Cipla are expected to see growth driven by their innovative medicines portfolios and recent launches.
The US market, however, is expected to be a challenge, with overall US sales projected to decline by 4% quarter-on-quarter due to lower Revlimid sales. Excluding Revlimid, US generic sales are forecast to grow by 2% quarter-on-quarter, driven by volume expansion in existing products and the benefits from recent launches. Overall, while the loss of Revlimid patent exclusivity will be a significant challenge for Indian pharmaceutical companies, their domestic growth and innovative medicines portfolios are expected to provide some resilience and drive overall revenue growth.
Stock Market Updates for Lupin
Recent Updates
Lupin partners with Gan & Lee to bring fortnightly GLP-1 treatment to India through exclusive licensing deal.
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and weight management in overweight and obese adults, offering a reduced injection frequency compared to existing weekly GLP-1 therapies. Clinical data shows that the drug delivers comparable or better weight loss and glycaemic control outcomes, with a safety and tolerability profile consistent with the GLP-1 class.
The agreement strengthens Lupin’s metabolic health portfolio and marks its entry into the obesity treatment segment. India faces a significant burden of metabolic diseases, with an estimated 90 million adults living with diabetes and 50 million classified as obese. The convenience of a fortnightly dosing regimen may improve treatment adherence for patients requiring long-term therapy. Lupin’s Managing Director, Nilesh Gupta, commented that the agreement reflects the company’s commitment to expanding access to innovative therapies for chronic metabolic conditions.
The partnership also aligns with Gan&Lee Pharmaceuticals’ strategy to expand globally and bring its innovations to new markets. The company is a leading insulin manufacturer in China and has received regulatory approvals in multiple international markets. Lupin Limited, headquartered in Mumbai, operates in over 100 markets worldwide, with a strong presence in India and the United States. The company manufactures a range of products, including branded and generic formulations, complex generics, biotechnology products, and APIs, across 15 manufacturing sites and seven research centers globally.
The agreement is expected to benefit patients in India, where there is a growing need for effective treatments for metabolic diseases. With its strong presence in the Indian market, Lupin is well-positioned to commercialize Bofanglutide and make it accessible to patients who need it. The partnership between Lupin and Gan&Lee Pharmaceuticals is a significant development in the field of metabolic health and is expected to have a positive impact on the lives of millions of people in India and beyond.
PolyPeptide forms partnership with Lupin | Speciality Chemicals Magazine
PolyPeptide, a leading manufacturer of peptides, has formed a strategic alliance with Lupin Manufacturing Solutions. The partnership aims to establish a framework for long-term cooperation, focusing on integrated procurement and supply planning for select raw materials. This alliance will enable PolyPeptide to diversify its sourcing options for key materials, including metabolites, and create a more robust and flexible supply chain for peptide manufacturing.
The demand for peptides has been increasing, and this alliance will help PolyPeptide to better meet the growing needs of its customers. By collaborating with Lupin Manufacturing Solutions, PolyPeptide will be able to secure a stable supply of essential raw materials, reducing its dependence on a single supplier and minimizing potential risks.
This partnership is the second significant collaboration announced by PolyPeptide in recent times. The company has also signed a collaboration agreement with Lifecore Biomedical, a contract development and manufacturing organization (CDMO). The agreement combines PolyPeptide’s expertise in peptide manufacturing and development with Lifecore’s capabilities in formulation, fill-finish, and packaging.
The partnership with Lifecore Biomedical will provide US-based manufacturers of peptide drugs with an integrated, end-to-end solution. The collaboration will enable a seamless transition between drug substance and drug product, streamlining the manufacturing process and reducing costs. By offering a comprehensive solution, PolyPeptide and Lifecore Biomedical aim to become the preferred partners for companies developing peptide-based drugs.
The financial details of both alliances have not been disclosed. However, these partnerships demonstrate PolyPeptide’s commitment to enhancing its capabilities and expanding its reach in the peptide manufacturing market. By forming strategic alliances with other industry leaders, PolyPeptide is well-positioned to capitalize on the growing demand for peptides and maintain its position as a leading manufacturer in the industry.
The alliances with Lupin Manufacturing Solutions and Lifecore Biomedical will enable PolyPeptide to improve its supply chain, reduce costs, and offer a more comprehensive range of services to its customers. As the demand for peptides continues to increase, PolyPeptide’s strategic partnerships will play a crucial role in driving its growth and success in the market.
Vitabiotics, owned by the Lalvani family, is reportedly in talks for a Rs 11,800 crore buyout, with the Lupin Eyes deal putting the brand under scrutiny.
The pharmaceutical company, Lupin, is reportedly in discussions to acquire Vitabiotics, a UK-based vitamins and supplements manufacturer, in a deal estimated to be worth £1 billion (approximately Rs 11,800 crore). Vitabiotics is a family-owned brand, founded by the Lalvani family, and is known for its popular brands such as Pregnacare, Osteocare, and Wellman.
The potential acquisition is seen as a strategic move by Lupin to expand its presence in the global vitamins and supplements market. Vitabiotics has a strong presence in the UK and other European countries, and its products are also sold in several other markets, including Asia and the Americas. The company has a reputation for producing high-quality products and has a strong distribution network.
If the deal goes through, it would be one of the largest acquisitions by an Indian pharmaceutical company in recent years. Lupin has been looking to expand its portfolio and presence in the global market, and the acquisition of Vitabiotics would help the company to achieve this goal.
The Lalvani family, which owns Vitabiotics, has been considering options for the future of the company, including a potential sale. The family has built the company into a successful and respected brand over several decades, and the sale would likely be a significant exit for the family.
The acquisition would also provide Lupin with access to new markets and distribution channels, as well as a portfolio of well-known and respected brands. Vitabiotics has a strong research and development capability, which would also be a valuable asset for Lupin.
Overall, the potential acquisition of Vitabiotics by Lupin is a significant development in the pharmaceutical industry, and would be a major milestone for both companies. The deal would require regulatory approvals and would be subject to due diligence and other conditions, but if it goes through, it would be a major expansion of Lupin’s presence in the global market.
Lupin’s chart patterns reveal a Golden Cross formation, hinting at a possible upcoming bullish trend reversal.
The Golden Cross is a technical indicator that suggests a trend reversal from bearish to bullish, occurring when the 50-day moving average (DMA) moves above the 200 DMA. For Lupin, a pharmaceutical company, this event may mark the beginning of a recovery phase after a period of mixed performance. Despite a year-to-date decline of 11.48%, Lupin has recorded gains of 8.32% and 9.39% over the past month and three months, respectively, outpacing the Sensex’s returns.
Technical indicators, such as the daily moving averages, Moving Average Convergence Divergence (MACD), and Bollinger Bands, support the bullish outlook. The On-Balance Volume (OBV) indicators also lean towards bullishness, suggesting that trading volumes support upward price movement. However, monthly MACD and KST indicators present a mildly bearish tone, indicating some caution in the longer term.
Lupin’s longer-term performance is mixed, with a three-year return of 183.63% and a five-year return of 133.35%, outperforming the Sensex. However, the 10-year performance shows Lupin lagging behind the Sensex. The current market capitalization of Rs 94,870 crore places Lupin in the large-cap category, which tends to exhibit more stable price movements.
Valuation metrics suggest that Lupin’s price-to-earnings (P/E) ratio is below the industry average, making it an attractive option for investors seeking exposure to the sector at a moderate valuation level. The formation of the Golden Cross can attract increased attention from traders and investors, but it is essential to consider this signal alongside other market factors and fundamental data.
Investors should factor in sector dynamics and consider Lupin’s valuation and medium-term returns. The Golden Cross event adds a compelling technical dimension to Lupin’s market assessment, signaling a potential bullish breakout. While longer-term indicators remain mixed, Lupin’s valuation and medium-term returns provide a context that could support further gains if market conditions remain favorable. Market participants should monitor Lupin’s price action and volume trends closely, considering the Golden Cross as part of a broader analytical framework.